Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Other Non Operating Income (2016 - 2026)

Lisata Therapeutics filings provide 14 years of Other Non Operating Income readings, the most recent being -$54000.0 for Q1 2026.

  • On a quarterly basis, Other Non Operating Income rose 48.57% to -$54000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$95000.0, a 45.71% increase, with the full-year FY2025 number at -$145000.0, up 43.58% from a year prior.
  • Other Non Operating Income hit -$54000.0 in Q1 2026 for Lisata Therapeutics, down from -$16000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of -$7000.0 in Q2 2025 to a low of -$187000.0 in Q1 2024.
  • Median Other Non Operating Income over the past 4 years was -$16000.0 (2025), compared with a mean of -$49384.6.
  • The widest YoY moves for Other Non Operating Income: up 90.67% in 2024, down 1338.46% in 2024.
  • Lisata Therapeutics' Other Non Operating Income stood at -$11000.0 in 2023, then changed by 0.0% to -$11000.0 in 2024, then tumbled by 45.45% to -$16000.0 in 2025, then plummeted by 237.5% to -$54000.0 in 2026.
  • The last three reported values for Other Non Operating Income were -$54000.0 (Q1 2026), -$16000.0 (Q4 2025), and -$18000.0 (Q3 2025) per Business Quant data.